New immunotherapy MK-1045 shows promise for tough lymphomas
NCT ID NCT07519772
First seen Apr 10, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This study tests a new immunotherapy drug, MK-1045, in about 200 people with two types of non-Hodgkin lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) that have not responded to at least two prior treatments. The main goals are to check safety and see if the cancer shrinks or disappears. Participants receive MK-1045 alone or with other anticancer drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Haddasah Medical Center ( Site 0600)
RECRUITINGJerusalem, 9112001, Israel
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.